Company intelligence

Silence Therapeutics

Biotech

Is this your company? Get featured or correct your listing →

Suggest a correction

Recent changes

  1. Oct 19, 2026Acquired for $1.3B equity value SEC EDGAR (Business Wire via Form 8-K)
  2. Oct 19, 2026Silence Therapeutics Sells For $1.3B | 130% Premium From Merck KGaA Pulse story

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Oct 19, 2026acquisition$1.3B equity value—
SEC EDGAR (Business Wire via Form 8-K)

Latest Pulse

  1. Silence Therapeutics Sells For $1.3B | 130% Premium From Merck KGaAMerck KGaA, Darmstadt, Germany agreed to acquire Silence Therapeutics in an all-cash deal worth about $1.3 billion in equity value, paying $20.00 per ADS -- a 130% premium to Friday's close -- to get full control of its lead siRNA drug Divesiran.→

Coverage Timeline

newest first
  1. Oct 19, 2026BIG TECHSilence Therapeutics Sells For $1.3B | 130% Premium From Merck KGaA$1.3B Acquisition→

All Coverage

BIG TECH

Silence Therapeutics Sells For $1.3B | 130% Premium From Merck KGaA

Illustration for: Silence Therapeutics Sells For $1.3B | 130% Premium From Merck KGaA
BIG TECH$1.3B Acquisition

Silence Therapeutics Sells For $1.3B | 130% Premium From Merck KGaA

Merck KGaA, Darmstadt, Germany agreed to acquire Silence Therapeutics in an all-cash deal worth about $1.3 billion in equity value, paying $20.00 per ADS -- a 130% premium to Friday's close -- to get full control of its lead siRNA drug Divesiran.

DEEP DIVE

Related Companies

Same sector
Scribe TherapeuticsAttovia TherapeuticsIambic TherapeuticsApnimedRetension PharmaceuticalsEli Lilly
Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction